Pfizer and BioNTech Initiate Rolling Submission of BLA for the US FDA's Approval of their COVID-19 Vaccine
Shots:
- The companies initiate the BLA with the FDA for approval of the COVID-19 vaccine in patients aged ≥16yrs. The data supporting the BLA will be submitted on a rolling basis over the coming wks.- with a request for Priority Review
- Additionally- the companies will submit the required manufacturing & facility data for licensure to complete the BLA. The vaccine is currently available in the US under a EUA granted from FDA on Dec 11- 2020- while 170M+ doses have been delivered in the US
- The companies have also applied to expand the current EUA for the COVID-19 vaccine to include individuals aged 12-15yrs. and plans to submit sBLA in this age group once the required 6 mos. data are available
Ref: BUSINESS WIRE | Image: Pfizer
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com